Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance

Michael W. Jann, Stephen R. Saklad, Larry Ereshefsky, Ann L. Richards, Charles A. Harrington, Chester M. Davis

    Research output: Contribution to journalArticle

    113 Scopus citations

    Abstract

    Plasma concentrations of haloperidol and its reduced metabolite (reduced haloperidol) were investigated in cigarette smokers (N=23) and nonsmokers (N=27). Steady-state plasma concentrations were obtained 12 h post bedtime dose. Haloperidol and reduced haloperidol concentrations were determined by RIA. Reduced haloperidol was separated by selective succinylation and liquid chromatography. Patients were clinically assessed with the Clinical Global Impression Scale (CGIS). Smokers had significantly lower haloperidol and reduced haloperidol plasma concentrations than nonsmokers (P<0.01, P<0.05). Clearance of haloperidol was significantly greater in smokers compared to nonsmokers (P=0.0052). CGIS assessments did not show significant differences between smokers and non-smokers. Plasma concentrations should be carefully monitored when patients either start or stop smoking.

    Original languageEnglish (US)
    Pages (from-to)468-470
    Number of pages3
    JournalPsychopharmacology
    Volume90
    Issue number4
    DOIs
    StatePublished - Dec 1 1986

    Keywords

    • Clearance
    • Haloperidol
    • Plasma concentrations
    • Reduced haloperidol
    • Smoking

    ASJC Scopus subject areas

    • Pharmacology

    Fingerprint Dive into the research topics of 'Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance'. Together they form a unique fingerprint.

    Cite this